Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing

A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades.

In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients. The trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.

Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs.

  • searabbit@piefed.social
    link
    fedilink
    English
    arrow-up
    20
    ·
    2 days ago

    From the article (maybe someone more knowledgeable can explain further):

    Daraxonrasib is a KRAS inhibitor treatment, which works by locking on to and shutting off certain mutations found in most pancreatic cancers. These mutations drive tumour growth.

    There are hopes the treatment could work for dozens of other cancers because they can have similar mutations.

    • bad1080@piefed.social
      link
      fedilink
      English
      arrow-up
      12
      ·
      edit-2
      2 days ago

      thank you!

      edit:

      KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients

      from: https://www.nature.com/articles/s41586-023-06123-3